ABBV-295
A Study to Assess Adverse Events, Tolerability, and Pharmacokinetics of Subcutaneous Injections of ABBV-295 in Healthy Adult Japanese Participants With Overweight or Obesity.
AbbVie · Phase 1 · Active, not recruiting · Enrollment 24
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| ABBV-295 Part 1 | n/r | n/r | n/r | n/r |
| Placebo for ABBV-295 Part 1 | n/r | n/r | n/r | n/r |
| ABBV-295 Part 2 | n/r | n/r | n/r | n/r |
| Placebo for ABBV-295 Part 2 | n/r | n/r | n/r | n/r |
Not shown
- ABBV-295 Part 1: endpoint not reported
- Placebo for ABBV-295 Part 1: endpoint not reported
- ABBV-295 Part 2: endpoint not reported
- Placebo for ABBV-295 Part 2: endpoint not reported